October 23rd 2024
This new indication for the bivalent respiratory syncytial virus prefusion F vaccine (Abrysvo) makes it the broadest currently available.
October 21st 2024
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
6th Annual Advanced Practice Collaborative
View More
Community Practice Connections™: 24th Annual International Lung Cancer Congress®
View More
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations
View More
Shaping the Management of COPD with Biologic Therapy
View More
Let’s Get “Real”: Alpha-1 Antitrypsin Deficiency—Case-Based Perspectives on Managing Associated Emphysema
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
EGPA: Highlighting the Patient Journey to Improve the Differential Diagnosis and Accelerate the Initiation of Guideline-Based Care
View More
Identifying Actionable Biomarkers in NSCLC: Real World Case Discussions on Applications of Testing in the Treatment Planning Process
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Improving Outcomes Across Frontline and R/R SCLC Care in Community Treatment Settings
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
Charting the Path to Precision Diagnosis: Detection and Treatment Approaches for Oncogenic Mutations in NSCLC
View More
Community Practice Connections™: The 2nd Annual Hawaii Lung Cancers Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Surv.AI Says: Real-World Insights Into the Journey for Patients With Pulmonary Arterial Hypertension
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Sotrovimab Distribution Paused in Areas Where BA.2 Is Dominant COVID-19 Variant
March 28th 2022The Assistant Secretary for Preparedness and Response (ASPR) announced a pause in sotrovimab distribution in regions where BA.2 is the dominant COVID-19 variant, citing evidence that the monoclonal antibody therapy would not effectively neutralize the BA.2 Omicron variant.
Read More
Type 2 Diabetes Diagnosis More Likely After COVID-19 Infection
March 21st 2022A matched cohort study found COVID-19 infection increased the risk of new type 2 diabetes diagnosis. Compared to patients with acute upper respiratory tract infections, COVID-19 patients were 28% more likely to develop diabetes.
Read More
“Most Transmissible Variant” BA.2 Expected to Overtake Original Omicron Strain
March 21st 2022There are many unknowns about the BA.2 COVID-19 variant. It appears 50-60% more transmissible than the original Omicron variant, but health experts are mixed on whether cases will spike dramatically.
Read More
Children’s Duration of COVID-19 Immunity from Natural Infection
March 19th 2022A Texas study found children and adolescents who previously contracted COVID-19 retained protective antibodies for 6 or more months after infection. However, natural infection plus vaccination remains the best defense against COVID-19.
Read More
With New Variants, COVID-19 Vaccination Mildly Effective in Children
March 15th 2022In children and adolescents, the Pfizer-BioNTech vaccine was only mildly effective against symptomatic and asymptomatic COVID-19 infections. Broken down by variant, Omicron infections were more likely to occur and more likely to be asymptomatic.
Read More
Effects of Switching Antibiotics Mid-Treatment on Antimicrobial Resistance
March 9th 2022Using real-time genetic surveillance, investigators found bacterial infections rapidly develop resistance to antibiotics, only to have these gene mutations disappear within a few days of switching to a different treatment.
Read More